WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013117522) AURORA AND FLT3 KINASES MODULATORS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2013/117522 International Application No.: PCT/EP2013/052182
Publication Date: 15.08.2013 International Filing Date: 04.02.2013
IPC:
C07D 413/14 (2006.01) ,A61K 31/496 (2006.01) ,A61P 35/00 (2006.01)
Applicants: SAREUM LIMITED[GB/GB]; Unit 2A, Langford Arch London Road Pampisford Cambridge Cambridgeshire CB22 3FX, GB
Inventors: READER, John Charles; GB
Agent: SCHLICH; 9 St Catherine's Road Littlehampton West Sussex BN17 5HS, GB
Priority Data:
1202027.706.02.2012GB
Title (EN) AURORA AND FLT3 KINASES MODULATORS
(FR) MODULATEURS DES KINASES AURORA ET FLT3
Abstract: front page image
(EN) The invention provides a compound having the formula (1) useful as modulator of the activity of Aurora kinases and FLT3 kinases: and salts thereof; wherein: R1 is hydrogen or C1-2 alkyl; and R2, R3 and R4 are the same or different and each is selected from hydrogen, C1-2 alkyl, fluorine, chlorine, C1-2 alkoxy and trifluoromethyl, provided that no more than two of R2, R3 and R4 are other than hydrogen. Also provided are pharmaceutical compositions containing the compounds and their use in medicine, and in particular in the treatment of cancer.
(FR) La présente invention concerne un composé de formule (1) utile comme modulateur de l'activité des kinases Aurora et des kinases FLT3 : et ses sels; où R1 est un groupe hydrogène ou alkyle en C1-2; et R2, R3 et R4 sont identiques ou différents et chacun est choisi parmi un groupe hydrogène, alkyle en C1-2, fluor, chlore, alcoxy en C1-2 et trifluorométhyle, à condition que pas plus de deux R parmi R2, R3 et R4 soient autres qu'un groupe hydrogène. L'invention concerne également des compositions pharmaceutiques contenant les composés et leur utilisation en médicine, en particulier dans le traitement du cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)